-
1تقرير
المصدر: A Phase 1b Combination Study of INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105)
الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT03920839Test
-
2تقرير
المصدر: A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203)
الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT03679767Test
-
3تقرير
المؤلفون: Mirati Therapeutics Inc.
المصدر: A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation
الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT06039384Test
-
4تقرير
المصدر: A Phase 1/2 Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors
الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05949632Test
-
5تقرير
المصدر: A Phase 2 Study Evaluating INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive
الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05879822Test
-
6تقريرA Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
المصدر: A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05836324Test
-
7تقرير
المصدر: A Phase 1, Open-Label, Multicenter Study of INCA32459 in Participants With Select Advanced Malignancies
الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05577182Test
-
8تقرير
المصدر: A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors
الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT04989387Test
-
9تقرير
المصدر: An Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants With Advanced Malignancies Previously Enrolled in Studies of Pemigatinib
الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT04949191Test
-
10تقرير
المصدر: A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Parsaclisib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment
الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT04831944Test